Psychopharmacology

Pediatric Mental Health Training Award Winner Announced

Retrieved on: 
Thursday, December 8, 2022
Pediatrics, PPP, Psychosis, Mental health, Psychopharmacology, COVID19, Depression, Psychology, Bipolar disorder, REACH, ADHD, Oppositional defiant disorder, Psychiatry, American Academy of Child and Adolescent Psychiatry, Federally Qualified Health Center, Knowledge, PTSD, Saint Petersburg State Pediatric Medical University, FQHC, Caregiver, PCP, El Río, Medicine, Medicaid

New York, Dec. 08, 2022 (GLOBE NEWSWIRE) -- The REACH Institute, a 501c3 nonprofit dedicated to ensuring the most effective, scientifically proven mental health care reaches all children and families, announces the recipient of their first-ever Pediatric Mental Health Training Award.

Key Points: 
  • New York, Dec. 08, 2022 (GLOBE NEWSWIRE) -- The REACH Institute, a 501c3 nonprofit dedicated to ensuring the most effective, scientifically proven mental health care reaches all children and families, announces the recipient of their first-ever Pediatric Mental Health Training Award.
  • The award provides a non-profit organization and/or Federally Qualified Health Center (FQHC) that serves low-income communities with free pediatric mental health training for its healthcare providers, local schools, and/or family peer advocates.
  • Since 2006, REACH has been training pediatric PCPs, therapists, and health care institutions nationwide, on the most advanced evidence-based children’s mental health therapies.
  • Their evidenced-based training programs equip primary care providers, mental health clinicians, health care institutions, educators, and caregivers on the most advanced therapies to better diagnose, treat and manage child and adult mental health issues.

Pasithea Therapeutics to Present at Annual Meeting of the Antibody Society Conference

Retrieved on: 
Tuesday, December 6, 2022
Conference, Psychopharmacology, Sporadic group, Life expectancy, Multiple sclerosis, Behavior, Diagnosis, Noonan syndrome, Motor neuron, CNS, Chemistry, Heredity, National academy, Amyotrophy, ALS, FDA, Biotechnology, Death, Amyotrophic lateral sclerosis, Central nervous system, Spinal cord, Antibody, MIAMI, Alpha-5 beta-1, Neuroscience, Survival, KTTA, SOD1, Research, Neurodegeneration, Therapy, Integrin, Brain, Patient, Pharmaceutical industry

Pasithea’s discovery candidate, PAS-003, has a novel mechanism of action with the potential to improve clinical outcomes in patients with ALS.

Key Points: 
  • Pasithea’s discovery candidate, PAS-003, has a novel mechanism of action with the potential to improve clinical outcomes in patients with ALS.
  • “We’re pleased to present our data at such a prestigious annual conference that includes a keynote address by this year’s Nobel Laureate for chemistry,” commented Dr. Steinman.
  • Pasithea Therapeutics is a biotechnology company primarily focused on the discovery, research and development of innovative treatments for central nervous system (CNS) disorders.
  • PAS-003 is monoclonal antibody targeting alpha5/beta1 integrin for the treatment of Amyotrophic Lateral Sclerosis (ALS) and other neurological diseases.

HMP Global's Psych Congress launches NP Institute In-Person event, new educational offering specifically for psychiatric nurse practitioners

Retrieved on: 
Tuesday, December 13, 2022
VRTX, APRN, EMT, LINC, Chicago, Bipolar, Schizophrenia, Learning, Health, Patient, Nursing, RN, Hunger, Stabilizer (aeronautics), Anxiety, Committee, University of Illinois at Chicago, Evolution, MS, Knowledge, Family, Symposium, SAWC, Psychiatry, NPS, University of California, Mental health, EMS, Practice management, News, Psych, University, Education, Documentation, NP, Mental disorder, Psychopharmacology, Congress, Depression, ADHD, CNS, Practitioner, Medicine, Pharmaceutical industry, Doctor of Philosophy, Psychotherapy

MALVERN, Pa. , Dec. 13, 2022 /PRNewswire-PRWeb/ -- Nurse practitioners in the psychiatric field have a robust new opportunity to grow their knowledge of psychopharmacology through the Psych Congress NP Institute In-Person event, featuring an interactive educational program which takes a deep dive into foundational principles and terminology on treatment, disease states, and medication classes.

Key Points: 
  • The inaugural Psych Congress NP Institute In-Person event will take place April 28 May 1 in Boston.
  • This essential educational experience is crafted by the world-class experts of Psych Congress, the United States' largest independent mental health educational conference and a forum for the entire mental health team.
  • The Psych Congress NP Institute In-Person event will help grow that confidence and a solid footing for building their psychopharmacological practice and provide resources for ongoing education for years to come."
  • For 36 years, Psych Congress has delivered practical, case-based education to an exceptional community of mental healthcare providers across the U.S.

Pasithea Therapeutics Postpones Special Meeting until December 9, 2022 at 9:00 AM Eastern Time

Retrieved on: 
Tuesday, November 29, 2022
LP, Noonan syndrome, Special, MIAMI, KTTA, SPECIAL, Amyotrophy, Therapy, Central nervous system, Vanderbilt Avenue, CNS, Amyotrophic lateral sclerosis, Security (finance), Concord, ALS, Research, Psychopharmacology, Multiple sclerosis

The Special Meeting will now be held onDecember 9, 2022at9:00 am Eastern Timeat One Vanderbilt Avenue, 67th Floor, New York, NY 10017.

Key Points: 
  • The Special Meeting will now be held onDecember 9, 2022at9:00 am Eastern Timeat One Vanderbilt Avenue, 67th Floor, New York, NY 10017.
  • There have been nochanges to the proposals to be voted on at the Special Meeting.
  • The record date for the Special Meeting remains November 9, 2022.
  • In connection with the Special Meeting, the Company filed a definitive proxy statement on Schedule 14A on November 15, 2022, with the Securities and Exchange Commission (the SEC).

CBC-backed ABio-X appoints pharmaceutical and healthcare veteran Dr. Jeffrey Jonas as CEO

Retrieved on: 
Thursday, November 10, 2022
Forest Laboratories, 2021 Essex County Council election, Shire (pharmaceutical company), Harvard University, Series, McLean Hospital, Kinetic, Amherst College, Nasdaq, Alembic Pharmaceuticals, Efficiency, Therapy, Psychopharmacology, Harvard Medical School, Regenerative medicine, Solution, Time, Drug development, Cancer, Psychiatry, Patient, CEO, Book, Industry, Pharmaceutical industry, Management

Dr. Jonas brings with him more than 25 years of experience in drug development and discovery across multiple therapeutic areas in the pharmaceutical and healthcare industries.

Key Points: 
  • Dr. Jonas brings with him more than 25 years of experience in drug development and discovery across multiple therapeutic areas in the pharmaceutical and healthcare industries.
  • Before Shire, Dr. Jonas served as Executive Vice President of ISIS Pharmaceuticals and held senior positions at Forest Laboratories, Inc. and Upjohn Laboratories.
  • I see tremendous potential in the platform and am excited to be helping the next generation of healthcare companies.
  • CBC Group, Asia's largest healthcare-dedicated asset management firm, focuses on platform-building, buyout, credit/royalty, and real estate across healthcare sectors, including pharmaceutical and biotech, medical technology and healthcare services.

EQS-News: A New BioTech Research Race Is Focused On Improving Life For MS Patients

Retrieved on: 
Friday, October 28, 2022
MS, Multiple sclerosis, Lists of diseases, Virus, CNS, Immune tolerance, AstraZeneca, Central nervous system, NASDAQ, KTTA, Diagnosis, Brain, Risk, Chinese, Ketamine, Neurodegeneration, Vaccine, BioNTech, JNJ, National, Chinese University of Hong Kong, Patient, Technology, Amyotrophic lateral sclerosis, Johnson & Johnson, BNTX, Spinal cord, Immune system, Research, COVID-19, Amyotrophy, Modified, Attention, Psychiatry, MRNA, Therapy, Biomarker, Psychopharmacology, RNA transfection, ALS, NYSE, Health status of Asian Americans, Animal, Advertising, Pharmaceutical industry, Medical device, MVA, Moderna, Pasithea (Charites), Science

As companies launch new products and research, government initiatives are projected to improve the accessibility of care and treatment.

Key Points: 
  • As companies launch new products and research, government initiatives are projected to improve the accessibility of care and treatment.
  • The rising MS numbers are believed to be the primary catalyst in market expansion.
  • Some are finding new research showing that an mRNA vaccine might also work in multiple sclerosis (MS).
  • Another recent article in Science showed published research that scientists have discovered about the risk of an individual contracting MS.

Pasithea Therapeutics to Present Tolerizing Vaccine Program Results at Immunotherapy 2022 International Course and Symposium

Retrieved on: 
Monday, October 17, 2022
MIAMI, Immunology, University of Navarra, SEC, Therapy, Amyotrophic lateral sclerosis, Spinal cord, MS, Nerve, Autoimmune disease, Nobel Prize in Physiology or Medicine, Multiple sclerosis, Association of Environmental Engineering and Science Professors, National Academy of Sciences, RRMS, Optic nerve, Nobel Prize, NASDAQ, Neuroscience, Biotechnology, Psychopharmacology, Research, Program, ALS, Lists of diseases, Immunotherapy, University, Immune system, Immunization, Company, Department, Dana–Farber Cancer Institute, Neurology, CEO, University of Buenos Aires, Amyotrophy, CNS, GLOBE, Neurodegeneration, KTTA, Brain, DNA, Forward-looking statement, National academy, Noonan syndrome, Psychiatry, Central nervous system, Pharmaceutical industry, Medicine, Symposium

We look forward to presenting our data at an international forum with other world-renowned leaders in MS and immunotherapy, said Dr. Tiago Reis Marques, CEO, Pasithea.

Key Points: 
  • We look forward to presenting our data at an international forum with other world-renowned leaders in MS and immunotherapy, said Dr. Tiago Reis Marques, CEO, Pasithea.
  • The study results support the Companys ongoing commitment to the program and move us further along in our mission to uncover new and effective treatments for neurological disorders.
  • The field of neurology, particularly for disabling diseases such as MS, requires deep research into the nature of effective therapeutic and immunization solutions.
  • Pasithea Therapeutics is a biotechnology company primarily focused on the discovery, research and development of innovative treatments for central nervous system (CNS) disorders.

EQS-News: New Drugs And Therapies Are Giving MS And ALS Sufferers New Hope

Retrieved on: 
Monday, October 10, 2022
People, Quality of life, News, Muscle, Merck, Communication, Disease, Health status of White Americans, Therapy, Spinal cord, Amyotrophic lateral sclerosis, MS, Multiple sclerosis, Nerve Damage, Animal, Employment, NYSE, NASDAQ, Lists of diseases, Antibody, Cerev Del, Patient, Psychopharmacology, Research, NIH, Walking, HIV disease progression rates, ALS, Partnership, Motor neuron, Technology, Center, Immune system, SOD1, Disorder, Ketamine, Immune tolerance, National, Amyotrophy, Motor neuron disease, CNM, Advertising, CNS, Survival, Korea Disease Control and Prevention Agency, KTTA, Brain, Atrophy, Death, MRK, COVID-19, Psychiatry, Central nervous system, Neutralizing antibody, Pharmaceutical industry, Vaccine

People suffering from incurable neurological diseases such as multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS) hope new therapies and drugs will arrive sooner than later.

Key Points: 
  • People suffering from incurable neurological diseases such as multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS) hope new therapies and drugs will arrive sooner than later.
  • MS is a potentially disabling disease affecting the brain and spinal cord the bodys central nervous system.
  • The immune system of those with MS attacks the myelin, the protective sheath covering a persons nerve fibers.
  • Signs and symptoms of MS vary widely and depend on the amount of nerve damage and which nerves are affected.

Pasithea Therapeutics to Call Special Meeting of Stockholders

Retrieved on: 
Monday, October 3, 2022
CNS, Lists of diseases, GLOBE, Concord, U.S. Securities and Exchange Commission, Amyotrophy, SEC, Nasdaq, Research, Psychopharmacology, McDermott Will & Emery, Camac, KTTA, Ketamine, LLC, ALS, Therapy, Special, MIAMI, Communication, Security (finance), Multiple sclerosis, Patient, Forward-looking statement, Central nervous system, Board of directors, Amyotrophic lateral sclerosis, Board, Company, Psychiatry, Pharmaceutical industry, Shareholder

Pasithea will call a Special Meeting in accordance with the Companys bylaws.

Key Points: 
  • Pasithea will call a Special Meeting in accordance with the Companys bylaws.
  • Additional details about the Special Meeting will be forthcoming.
  • Pasithea Therapeutics Corporation is a biotechnology company focused on the discovery, research and development of new and effective treatments for central nervous system (CNS) disorders.
  • Pasithea, its directors and certain of its executive officers and employees are deemed to be participants in a solicitation of requests not to vote for the Camac Groups proposal at the Special Meeting (the Special Meeting Solicitation).

EQS-News: Biotech Company Pleased With Results Of Early Testing Demonstrating Vaccine Potential For Multiple Sclerosis

Retrieved on: 
Monday, October 3, 2022
National Academy of Sciences, MRNA, Injection, CNS, Vaccine, Lists of diseases, AstraZeneca, National academy, NASDAQ, Incidence, Advertising, Johnson & Johnson, Amyotrophy, Science, MS, EAE, Technology, Research, Disease, Nature, Psychopharmacology, Hooke, Natalizumab, Psychiatry, Brain, National, KTTA, COVID-19, Epstein–Barr virus, Ketamine, Immune system, Laboratory, ALS, Therapy, Spinal cord, NYSE, Autoimmune disease, Plasma, Multiple sclerosis, Patient, Central nervous system, Paralysis, Crohn's disease, Infection, EBV, White matter, DNA, Amyotrophic lateral sclerosis, Encephalitis, Histology, JNJ, Monkeypox, Pharmaceutical industry

Pasithea is a biotechnology company focused on discovering, researching and developing new and effective treatments for psychiatric and neurological disorders.

Key Points: 
  • Pasithea is a biotechnology company focused on discovering, researching and developing new and effective treatments for psychiatric and neurological disorders.
  • Pasithea recently announced encouraging preclinical results that support the efficacy of a tolerizing DNA vaccine for multiple sclerosis (MS).
  • Based on its experiments conducted with Hooke Laboratories Inc., Pasithea reported that intramuscular injections of the candidate vaccine (PAS002) delayed the onset of paralysis and reduced peak disease severity.
  • Moderna Inc. (NASDAQ: MRNA), meanwhile, has started testing the vaccine mRNA-1189 in Phase I studies but does not indicate MS, though the company believes it could potentially assist in prevention.